Key Takeaways
- Strong H1, softer H2 ahead: Revenue grew 18.5% YoY in Q2, but the full-year constant-currency growth guide was cut from high-teens to mid-teens as US biotech funding slows.
- Mix shift is pressuring margins: Material costs jumped 345 bps YoY to 29.4% of revenue, offsetting staff cost improvements and keeping EBITDA margins flat.
- Manufacturing and development drove the beat: Development and Manufacturing Services led performance, while Discovery Services felt the early pinch of a biotech funding reset.
- Capacity build-out continues: The company operationalized a new non-GMP API center, progressed the Stelis acquisition, and bought 17 acres in Hyderabad, signaling confidence in medium-term demand.
- What to watch next quarter: Whether the US biotech slowdown stabilizes or deepens, and how quickly the Stelis facility integration begins to contribute.
Revenue Performance & the Biotech Slowdown
- Broad-based H1 growth: Q2 revenue rose 18.5% YoY (15% in constant currency), with H1 up 21.6%, driven by Development and Manufacturing Services and sustained momentum in Dedicated Centers.
- Discovery Services softened: Global demand remained generally healthy, but US-based biotech clients showed slowed growth YoY as they adjusted to a new, tighter funding environment.
- The guide-down is contained: Management still expects continued growth, just at a lower level in H2, and framed the biotech slowdown as short-term while insisting long-term sector fundamentals remain strong.
- PAT tracked revenue: PAT before exceptional items grew 20% in Q2 and 23% in H1, with operating EBIT growth also tracking revenue growth.
Hunt: "Long term sector fundamentals remain strong and we expect continued growth but at a lower level in the second half of the year, this short-term slowing in the US biotech segment is reflected in our latest outlook."
Margin Structure & Cost Dynamics
- EBITDA margin held flat: Reported EBITDA margin was nearly flat at 29.6% in Q2 and 29.0% in H1 (vs 29.1% in H1 FY23), but the composition underneath shifted materially.
- Material costs surged on mix: Material costs as a percentage of revenue rose 345 bps YoY to 29.4% in Q2, and 302 bps to 28.5% in H1, driven by business mix tilting toward manufacturing services.
- Staff costs improved: Staff costs as a percentage of revenue improved 194 bps YoY to 26.5% in Q2, and 206 bps to 27.4% in H1, partially offsetting the material cost headwind.
- Other direct costs fell: Power, utility and clinical trial costs as a percentage of revenue improved 73 bps to 3.0% in Q2, and 171 bps to 6.4% in H1.
- Sequential margin recovery: EBITDA margin improved from 26.2% in Q1 to 27.9% in Q2; EBIT margin improved from 13.6% to 16.4%; PAT margin improved from 11.2% to 13.1%.
Capacity Expansion & Strategic Build-Out
- Non-GMP API capability added: A new non-GMP capability center was operationalized during Q2, adding the ability to conduct API synthesis in a non-GMP environment for agile, cost-effective early-phase development.
- Stelis acquisition progressing: The acquisition of a multi-modal facility (Unit 3) from Stelis Biopharma Ltd, announced in Q1, is moving forward, with 5.3 crore in transaction costs (net of tax) booked as an exceptional item in Q2.
- Hyderabad campus extended: The company purchased a 17-acre land parcel in Genome Valley, Hyderabad as an extension to its existing research campus.
- Mangalore facility cleared: Received regulatory approval from the US FDA for its commercial manufacturing facility in Mangalore.
- Zoetis partnership deepened: Commissioned a state-of-the-art, digitally-enabled Quality Control laboratory for biologics testing, featuring latest technology for higher throughput and seamless data transfer.
Hunt: "I am pleased to report a strong set of results for the second quarter and first half of the financial year, particularly in our Development and Manufacturing Services."
Investment Posture & H2 Priorities
- Investment spend stays elevated: Management will continue to invest in new science, technology and digitization, as well as building capacity to support future growth through H2.
- Discretionary spend gets balanced: The company plans to balance discretionary expenditure to maintain margins while still funding the capacity and capability build-out.
- No pause on strategic bets: The land purchase, Stelis acquisition progress, and new lab commissioning all signal that the investment cycle is not being curtailed despite the softer H2 revenue outlook.
Biswas: "During the second half of the year, we will continue to invest in new science, technology and digitization, as well as building capacity to support future growth, while balancing discretionary expenditure in order to maintain margins."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Mid-teens constant-currency growth (revised down from high-teens) | FY24 full year |
| Investment spend | Continue investing in science, technology, digitization and capacity | H2 FY24 |
| Margin management | Balance discretionary expenditure to maintain margins while investing | H2 FY24 |
| Stelis acquisition | Complete acquisition of multi-modal facility (Unit 3) from Stelis Biopharma | In progress, no date given |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue from operations | ₹910 crores, up 18.5% YoY, ~15% at constant currency |
| Reported revenue | ₹932 crores, up 19% YoY |
| EBITDA from operations | ₹254 crores, up 17.4% YoY |
| EBITDA from operations margin | 27.9%, down 27 bps YoY |
| Reported EBITDA | ₹276 crores, up 19% YoY |
| Reported EBITDA margin | 29.6%, flat YoY |
| EBIT from operations | ₹149.4 crores, up 18.4% YoY |
| EBIT from operations margin | 16.4%, down 1 bps YoY |
| PAT before exceptional items | ₹122 crores, up 20% YoY |
| PAT margin (before exceptional items) | 13.1%, up 7 bps YoY |
| PAT after exceptional items | ₹117 crores, up 14% YoY |
| Exceptional item (net of tax) | ₹5.3 crores, transaction costs for Stelis Biopharma facility acquisition |
| Revenue growth guidance (constant currency) | Mid-teens for FY24, revised from high teens |
| Cash and cash equivalents | ₹168.3 crores as of 30 Sep 2023 |
| Total borrowings | ₹519.9 crores as of 30 Sep 2023 |